ISHL congress2023-07-17T10:16:36+01:00

ISHL 2022 – hybrid, Cologne


Lecture Board: Heinz Ludwig, MD; Alison J. Moskowitz, MD; George Rassidakis, MD; Margaret A. Shipp, MD; Andrea Visentin, MD; Ioanna Xagoraris, MD
Publishing Editor: Anna Fenzl, PhD

Preface – ISHL 2022

Preface – ISHL 2022 ©MSKCC - Alison J. Moskowitz, MD, Memorial Sloan Kettering, Cancer Center and Weill Cornell, Medical College, New York, NY Dear Colleagues, The International Symposium on Hodgkin Lymphoma (ISHL) that was organized by the German Hodgkin Study Group (GHSG) and held in Cologne, Germany, and virtually from 22nd–24th October 2022 covered relevant aspects of Hodgkin’s lymphoma research as well as updates on current treatment strategies. This year, a novel session on cellular therapies featuring world-leading experts who discussed recent developments in basic research and clinical application was included. However, the main focus of this meeting was on older and frail patients as well as patients with early-stage disease. This issue of memo inHaematology offers findings presented at this year’s ISHL in the area of clinical research, immunological mechanisms, and new therapeutic agents. Trial results showed durable remissions with PD-1 blockade plus chemotherapy foll

Immunotherapy-based treatment of Hodgkin lymphoma: What is new?

Immunotherapy-based treatment of Hodgkin lymphoma: What is new? Second-line pembrolizumab in addition to GVD Immune-checkpoint blockade plays a key role in the therapeutic landscape of relapsed or refractory classical Hodgkin lymphoma (r/r cHL). Nevertheless, novel strategies to enhance responses remain of clinical interest. In the second-line setting, the phase II study presented by Moskowitz et al. at ISHL 2022 evaluated pembrolizumab in addition to up to four cycles of gemcitabine, vinorelbine, and liposomal doxorubicin (GVD) [1]. Thirty-nine patients were enrolled. The primary endpoint was complete response (CR) after 2–4 cycles. Patients who achieved CR after two cycles were eligible for autologous stem cell transplantation (ASCT). In the group of 38 evaluable patients, 92 % (n = 35) obtained CR after two cycles of pembrolizumab plus GVD. Including one additional patient achieving CR after two more cycles, the CR rate for this regimen was 95 %. ASCT was performed in 36 patient

Exploring immunological mechanisms and new therapeutic targets in HL

Exploring immunological mechanisms and new therapeutic targets in Hodgkin lymphoma Interplay between immune cells in anti-PD-1–treated cHL Basic scientific research efforts are aimed at improving the understanding of the activity of immune checkpoint inhibitors in classical Hodgkin lymphoma (cHL). At ISHL 2022, Paczkowska et al. presented results regarding peripheral immune responses to PD-1 blockade that were generated using single-cell RNA sequencing [1]. Also, the researchers sought to define non-CD8-T-cell–dependent mechanisms of immune evasion. Peripheral blood mononuclear cells were obtained from 13 healthy donors, 11 patients with newly diagnosed cHL, and 20 patients with relapsed/refractory cHL who were receiving anti-PD-1 treatment. After negative selection of CD3-positive and CD3-negative cells, these separated populations were submitted to RNA sequencing. Patients with the most favorable responses to PD-1 blockade had significantly higher CD4-positive T-cell receptor div


All downloads from ISHL 2022

ISHL 2022 Cover

Full report (english)